| 발표일자: |
2014년 4월 12일(토) ~ 4월 13일(일) |
| 발표번호: |
P(e-poster)-013 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| Late-onset intraocular pressure (IOP)-lowering efficacy of tafluprost monotherapy |
| 1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
2Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea |
| Mi Jeung Kim, MD(1,2), Jin Wook Jeoung, MD(1,2), Ki Ho Park, MD(1,2),Dong Myung Kim, MD(1,2) |
|
목적 : To investigate the late-onset intraocular pressure (IOP)–lowering efficacy of tafluprost monotherapy in patients with glaucoma
방법 : The medical records of patients with glaucoma who underwent tafluprost (Taflotan®) monotherapy as a first drug of choice for more than one year were reviewed retrospectively. The responder to tafluprost was defined as eyes showing more than 20% reduction of IOP from baseline. All patients were followed up within 3 months after the start of treatment, and then they were regularly followed up at 3-to 6-month intervals.
결과 : Eighty-seven eyes were enrolled (76 eyes with normal tension glaucoma, 11 eyes with primary open angle glaucoma). Overall follow-up period (20.8 months), 58 eyes (67%) were observed as responders to tafluprost, and 34 eyes (38%) responded within 3 months of therapy. Of the other 25 eyes (29%), 10 eyes responded to tafluprost after 3 months of therapy, 7 eyes after 6 months, 6 eyes after 12 months, and 2 eyes after 18 months of therapy. Thirteen eyes presented with side effects (ie, hyperemia, skin pigmentation and itching), then 2 eyes with hyperemia (2.3%) discontinued the treatment.
결론 : Significant numbers of responder to tafluprost monotherapy showed the late-onset IOP-lowering efficacy.
|
| |